Towa Pharmaceutical Co., Ltd. (TWAPF)

Market Cap	1.29B +39.9%
Revenue (ttm)	1.72B +6.5%
Net Income	136.77M +11.2%
EPS	2.78 +11.2%
Shares Out	n/a
PE Ratio	9.46
Forward PE	n/a
Dividend	0.52 (2.05%)
Ex-Dividend Date	Mar 30, 2026

Volume	200
Average Volume	150
Open	25.33
Previous Close	16.83
Day's Range	25.33 - 25.33
52-Week Range	16.83 - 25.33
Beta	-0.20
RSI	n/a
Earnings Date	May 14, 2026

About Towa Pharmaceutical

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare; disease risk testing services; and quasi drugs. In ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 4,788
• Stock Exchange: OTCMKTS
• Ticker Symbol: TWAPF

Financial Performance

In fiscal year 2025, Towa Pharmaceutical's revenue was 259.59 billion, an increase of 13.89% compared to the previous year's 227.93 billion. Earnings were 18.99 billion, an increase of 17.39%.

Financial numbers in JPY